Making Cents Sense

For most of my investing life, I believed the market rewarded courage. The loudest voices on financial television certainly seemed convinced of it. Every day there was a new revolutionary technology, a new hyper-growth stock, a new industry supposedly destined to change civilization forever. The message was always the same: if I wanted exceptional returns, I had to chase exceptional stories. And for a while, that idea made perfect sense. After all, growth is exciting. Income is boring. Nobody gathers around the water cooler to discuss a utility company raising its dividend by 4%. Nobody posts screenshots of a stable infrastructure fund generating predictable cash flow. Nobody brags at parties about owning a pipeline operator that quietly distributes income every quarter. Instead, people talk about the stock that doubled. The startup that exploded higher. The company that turned a thousand dollars into ten thousand. The financial media loves excitement because excitement generates atten...

For most investors, the stock market is a popularity contest. For me, it's a scavenger hunt. I'm not looking for the stocks everyone already loves. By the time financial television is discussing them nonstop and social media has turned them into cults, the easy money is often gone. The crowd has arrived. The narrative has formed. The expectations are sky-high. I'm looking for something different. I'm looking for catalysts. Specifically, I'm looking for moments when reality is changing faster than Wall Street's perception of reality. That's where pharmaceutical stocks become fascinating. Not because they're easy. Not because they're predictable. And certainly not because they don't occasionally resemble a casino run by molecular biologists. They're fascinating because few sectors create larger disconnects between present value and future value. A biotech company can look worthless today and become enormously valuable tomorrow. Like...

Why Money Never Sits Still, Why Investors Chase Yesterday’s Winners, and Why the Biggest Opportunities Often Appear When Nobody Wants Them If there's one lesson the market keeps teaching me, it's this: Money is restless. It never sits still. It never falls in love. It never stays loyal. It never cares about the story investors tell themselves. Capital is constantly searching for its next destination, moving from fear to optimism, from caution to speculation, from safety to innovation, and then right back again. Watching this happen is like watching human psychology perform interpretive dance while wearing a suit. Everyone thinks they're making rational decisions. Meanwhile, trillions of dollars are stampeding from one corner of the market to another because somebody used the phrase "AI opportunity" on an earnings call. The longer I invest, the more I realize that understanding capital rotation is often more important than understanding individual compan...

Why I Pay Attention to What Institutions Are Doing, Not Just What They're Saying If there's one lesson the stock market has taught me over the years, it's this: The market doesn't care what I think should happen. It cares what large institutions are actually doing with billions of dollars. That distinction sounds obvious, but investors repeatedly confuse sentiment with positioning. Sentiment is what people say. Positioning is what people do. And when I look at large-cap stocks, I've learned that those two things can be dramatically different. Some of the biggest gains I've ever seen came when institutions were quietly accumulating stocks while headlines remained negative. Likewise, some of the most painful declines happened when everyone sounded bullish even as institutional money was heading for the exits. The difference between sentiment and fundamentals—and how institutions navigate both—is one of the most misunderstood aspects of investing. Unders...